BNP/PUT/ELI LILLY & CO/900/0.1/19.12.25 Stock

DE000PC7ZJP9

Real-time Boerse Frankfurt Warrants 08:50:43 2024-07-16 am EDT
9.32 ^EUR	-1.27%

Current month	-11.53%
1 month	-20.47%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart BNP/PUT/ELI LILLY & CO/900/0.1/19.12.25

Latest news about ELI LILLY AND COMPANY

Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793	08:35am	MT
Novo owner backs Swiss biotech Asceneuron in $100 million round	03:00am	RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	Jul. 12	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	Jul. 12	RE

More news

Quotes 5-day view

Date	Price	Change
24-07-16	9.32	-1.27%
24-07-15	9.44	-1.15%
24-07-12	9.55	-4.60%
24-07-11	10.01	+3.41%
24-07-10	9.68	-2.12%

Real-time Boerse Frankfurt Warrants

Last update July 16, 2024 at 08:50 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	ELI LILLY AND COMPANY
Issuer	BNP Paribas
WKN	PC7ZJP
ISIN	DE000PC7ZJP9
Date issued	2024-04-09
Strike	900 $
Maturity	2025-12-19 (521 Days)
Parity	10 : 1
Emission price	15.04 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	20.23 €
Lowest since issue	8.99 €
Spread	0.03 €
Spread %	0.32%

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company